Nilvadipine

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	C08CA10 (WHO)
Identifiers
IUPAC name 3-Methyl 5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
CAS Number	75530-68-6 Y
PubChem CID	4494
DrugBank	DB06712 Y
ChemSpider	4338 N
UNII	0214FUT37J
KEGG	D01908 Y
ChEMBL	ChEMBL517427 N
CompTox Dashboard (EPA)	DTXSID2046624
ECHA InfoCard	100.232.871
Chemical and physical data
Formula	C19H19N3O6
Molar mass	385.376 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C
InChI InChI=1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3 N Key:FAIIFDPAEUKBEP-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Nilvadipine is a calcium channel blocker (CCB) used for the treatment of hypertension and chronic major cerebral artery occlusion.

Pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be decreased by nilvadipine.

Experimental research

Nilvadipine was tested in clinical trial as a possible treatment for Alzheimer's disease in Ireland by the Roskamp Institute, Florida, USA and Trinity College, Ireland.^[1] Following this study, an international research consortium led by Trinity College Dublin (Ireland) in May 2011 announced the selection for funding of a large-scale European clinical trial of nilvadipine. More than 500 Alzheimer's disease patients will participate in the multicenter phase III clinical trial designed to study the effectiveness of nilvadipine.^{[2][needs update]} In 2018, researchers analyzing data from the trial came to the conclusion that treatment with nilvadipine did not benefit the trial participants, who had suffered from mild to moderate Alzheimer disease.^[3]